Home/Filings/4/0001213900-26-000658
4//SEC Filing

Gabay Avraham 4

Accession 0001213900-26-000658

CIK 0001176309other

Filed

Jan 1, 7:00 PM ET

Accepted

Jan 2, 8:00 PM ET

Size

9.4 KB

Accession

0001213900-26-000658

Insider Transaction Report

Form 4
Period: 2025-12-31
Gabay Avraham
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2025-12-31+81,216515,256 total
  • Award

    Common Stock

    2025-12-31+115,000630,256 total
  • Award

    Performance Stock Units

    2025-12-31+19,00019,000 total
    Common Stock (19,000 underlying)
Footnotes (3)
  • [F1]Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.
  • [F2]Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
  • [F3]Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.

Documents

1 file

Issuer

ORAMED PHARMACEUTICALS INC.

CIK 0001176309

Entity typeother

Related Parties

1
  • filerCIK 0001777328

Filing Metadata

Form type
4
Filed
Jan 1, 7:00 PM ET
Accepted
Jan 2, 8:00 PM ET
Size
9.4 KB